Sentences with phrase «cancer tumor board»

Not exact matches

The Moores Cancer Center's Molecular Tumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard therCancer Center's Molecular Tumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard theraTumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard theratumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard thercancer or who have exhausted standard therapies.

In a paper published in the May 5 online issue of The Oncologist, researchers at the University of California, San Diego School of Medicine and Moores Cancer Center detail their experience evaluating 34 patients between December 2012 and June 2013 using a molecular tumor board — a new type of advisory group comprised of multidisciplinary experts, including those in the fields of tumor genetics, basic science and bioinformatics.

Coupled with a review of these results by experts on a molecular tumor board, the opportunity exists to identify novel therapies that would target specific abnormalities,» notes senior author of the work, Shridar Ganesan, MD, PhD, associate director for translational science at Rutgers Cancer Institute and associate professor of medicine and pharmacology at Rutgers Robert Wood Johnson Medical School.

Pediatric oncologists, surgeons, radiation oncologists, pathologists, radiologists and nuclear medicine physicians attend the Tumor Board, allowing for our collective expertise to provide a thorough, comprehensive approach to the care of children with cancer.

A board - certified general surgeon and surgical oncologist, Kevin Roggin, MD, specializes in the surgical treatment of complex upper gastrointestinal tract and hepato - pancreato - biliary (HPB) cancers (stomach, pancreas, liver, gallbladder, gastrointestinal stromal tumors (GIST), sarcomas, extrahepatic bile duct cholangiocarcinoma).

Recently, we partnered with the Siteman Cancer Center to establish the Genomics Tumor Board, which aims to apply rapid - turnaround sequencing to guide diagnosis and treatment of cancer patCancer Center to establish the Genomics Tumor Board, which aims to apply rapid - turnaround sequencing to guide diagnosis and treatment of cancer patcancer patients.

Pediatric oncologists, surgeons, radiation oncologists, pathologists, radiologists and nuclear medicine physicians attend the Tumor Board, allowing for our collective expertise to provide thorough, comprehensive approach to the care of children with cancer.

Christina Curtis, PhD, MSc is an Assistant Professor in the Departments of Medicine (Oncology) and Genetics at Stanford University School of Medicine where she leads the Cancer Systems Biology Group and serves as Co-Director of the Molecular Tumor Board at the Stanford Cancer Institute.

Title: Infiltrating immune cells in breast cancer subtypes Date / Time: Tuesday, April 17 2018, 8:00 am - 12:00 pm CT Author: J.L. Matta et al, Ponce Health Sciences Institute and H. Lee Moffitt Cancer Center Poster # / Location: 5698 / Section 32, Board 4 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7977 Demonstrates the value of combining PAM50 subtype distribution with tumor immune profiling to identify biologically distinct patient populations; the combination of these signatures could be applied to the development of specific immunotherapecancer subtypes Date / Time: Tuesday, April 17 2018, 8:00 am - 12:00 pm CT Author: J.L. Matta et al, Ponce Health Sciences Institute and H. Lee Moffitt Cancer Center Poster # / Location: 5698 / Section 32, Board 4 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7977 Demonstrates the value of combining PAM50 subtype distribution with tumor immune profiling to identify biologically distinct patient populations; the combination of these signatures could be applied to the development of specific immunotherapeCancer Center Poster # / Location: 5698 / Section 32, Board 4 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7977 Demonstrates the value of combining PAM50 subtype distribution with tumor immune profiling to identify biologically distinct patient populations; the combination of these signatures could be applied to the development of specific immunotherapeutics.

Cancer Imaging and Radiobiology's presence in the clinical sphere is broad and significant including participation in Norris Cotton Cancer Center Tumor Boards held at Dartmouth Hitchcock Medical Center in Lebanon, NH.

Paris Descartes APHP and INSERM Poster # / Location: 4546 / Section 25, Board 1 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7648 The tumor inflammation signature (TIS) and other gene expression signatures, simultaneously analyzed using the IO 360 panel, predict clinical benefit of anti-PD1 treatment (nivolumab and pembrolizumab) in «real life» patients with various cancer types, including NSCLC.

Title: The immune microenvironment in hormone receptor - positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumab Date / Time: Tuesday, April 17 2018, 1:00 pm - 5:00 pm CT Author: A. Waks et al, Dana Farber Cancer Institute Poster # / Location: 4565 / Section 26, Board 1 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7859 HR + / HER2 - breast tumors with higher levels of tumor immune activity have a more favorable response to chemo plus bevacicancer and treatment outcome following preoperative chemotherapy plus bevacizumab Date / Time: Tuesday, April 17 2018, 1:00 pm - 5:00 pm CT Author: A. Waks et al, Dana Farber Cancer Institute Poster # / Location: 4565 / Section 26, Board 1 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7859 HR + / HER2 - breast tumors with higher levels of tumor immune activity have a more favorable response to chemo plus bevaciCancer Institute Poster # / Location: 4565 / Section 26, Board 1 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7859 HR + / HER2 - breast tumors with higher levels of tumor immune activity have a more favorable response to chemo plus bevacizumab.

With advanced treatment - planning software and a board - certified radiation oncologist, our cancer patients benefit from customized treatment plans and sub-millimeter precision that enable the delivery of high - dose radiation directly to the tumor with minimum radiation exposure to the surrounding healthy anatomy.

Assist with the preparation, setup, and facilitation of tumor board conferences and cancer committee meetings.